CLINICAL TRIALS

• MK-7009 study (Merck): A phase 1b drug trial to test the safety and efficacy of MK-7009. Subjects will participate in the study for approximately 10 weeks. Recruiting subjects ages 18-55 who are treatment-naïve HCV genotype 1
• Prophesys study (Roche): An observational study. Studies the effects of combination treatment on HCV infected patients. Subjects will participate in the study for their HCV treatment duration plus a 24-week follow-up. Recruiting treatment-naïve subjects with HCV aged ≥ 18 years.
• Ncore study (Roche): A randomized trial examining the effects of 24 weeks vs. 48 weeks of combination therapy with PEGASYS® plus COPEGUS ® on SVR. Subjects will participate for a total of 72 weeks, either 24 weeks treatment and 48 weeks follow-up, or 48 weeks treatment and 24 weeks follow-up. Recruiting previously treatment-naïve subjects aged ≥ 18 with HCV genotypes 2 and 3 who have been on treatment for 4 weeks and have not achieved RVR.
• NIM811 study (Novartis): A phase 1 trial to test the safety and efficacy of NIM811 in conjunction with monotherapy or combination therapy. Subjects will participate for about 2 ½ months, with a 2-week treatment period. MGH will be recruiting for cohort 8 of this study, which is NIM811 or placebo in conjunction with monotherapy. Recruiting treatment-naïve genotype 1 HCV subjects aged ≥ 18 years. As an incentive, subjects participating in this cohort will receive standard of care for HCV paid for by Novartis upon conclusion of their participation.
• Nitazoxanide study (Romark): A phase 2 trial to test the safety and efficacy of nitazoxanide in conjunction with combination therapy. Subjects will participate in this study for 52 weeks of treatment followed by 24 weeks of follow-up. Recruiting treatment-naïve genotype 1 subjects aged ≥ 18 years.

« Return to MGH Center for Viral Hepatitis